Literature DB >> 17904301

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.

Sanjeev Kotwal1, Ananya Choudhury, Colin Johnston, Alan B Paul, Peter Whelan, Anne E Kiltie.   

Abstract

PURPOSE: To conduct a retrospective analysis within a large university teaching hospital, comparing outcomes between patients receiving either radical surgery or radiotherapy as curative treatment for bladder cancer. PATIENTS AND METHODS: Between March 1996 and December 2000, 169 patients were treated radically for muscle-invasive bladder cancer. Data were collected from patient notes. Statistical analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression analysis to compare radiotherapy and surgical outcome data.
RESULTS: There was no difference in overall, cause-specific, and distant recurrence-free survival at 5 years between the two groups, despite the radiotherapy group being older (median age, 75.3 years vs. 68.2 years). There were 31 local bladder recurrences in the radiotherapy group (24 solitary), but there was no significant difference in distant recurrence-free survival. In a more recent (2002-2006) cohort, the median age of radiotherapy patients but not the cystectomy patients was higher than in the 1996-2000 cohort (78.4 years vs. 75.3 years for radiotherapy and 67.9 years vs. 68.2 years for surgery).
CONCLUSIONS: Although the patients undergoing radical cystectomy were significantly younger than the radiotherapy patients, treatment modality did not influence survival. Bladder cancer patients are an increasingly elderly group. Radical radiotherapy is a viable treatment option for these patients, with the advantage of organ preservation.

Entities:  

Mesh:

Year:  2007        PMID: 17904301     DOI: 10.1016/j.ijrobp.2007.06.030

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  39 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

Review 2.  Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.

Authors:  Yuanbin Ru; Garrett M Dancik; Dan Theodorescu
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

3.  Treatment results of radiation therapy for muscle-invasive bladder cancer.

Authors:  Tanja Langsenlehner; Carmen Döller; Franz Quehenberger; Heidi Stranzl-Lawatsch; Uwe Langsenlehner; Karl Pummer; Karin S Kapp
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

4.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

5.  Hypofractionated palliative radiotherapy for bladder cancer.

Authors:  Piet Dirix; Sofie Vingerhoedt; Steven Joniau; Ben Van Cleynenbreugel; Karin Haustermans
Journal:  Support Care Cancer       Date:  2015-05-16       Impact factor: 3.603

6.  Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Authors:  Shuo Zhang; Yong-Hua Yu; Yong Zhang; Wei Qu; Jia Li
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 7.  [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?]

Authors:  D Bottke; C Bolenz; S Ott; A Cebulla; T Wiegel
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

8.  Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.

Authors:  Fabrícia Dietrich; Fabrício Figueiró; Eduardo Cremonese Filippi-Chiela; Angélica Regina Cappellari; Liliana Rockenbach; Alain Tremblay; Patrícia Boni de Paula; Rafael Roesler; Aroldo Braga Filho; Jean Sévigny; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

Review 9.  Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control.

Authors:  George A Plataniotis; Roger G Dale
Journal:  World J Radiol       Date:  2013-08-28

Review 10.  Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Authors:  Colin P N Dinney; Donna Hansel; David McConkey; William Shipley; Michael Hagan; Robert Dreicer; Seth Lerner; Bogdan Czerniak; Fred Waldman; Susan Groshen; Lawrence D True; Emanuel Petricoin; Dan Theodorescu; Andrew Hruszkewycz; Dean Bajorin
Journal:  Urol Oncol       Date:  2014-10-24       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.